55 results about "Tumor Pathology" patented technology

The invention belongs to a case register network management system, and particularly relates to a kidney cancer case digitized information management system. The system comprises a kidney cancer data management platform, a sample library, an image data platform and a tumor pathology result data platform. By means of the kidney cancer case digitized information management system, management of clinical case data can be conducted, a doctor can track and monitor over the illness changes of the kidney cancer of a patient, and the kidney cancer clinical scientific research is carried out assisted by the system, and the system meets the requirements of existing evidence-based medicine.

The invention provides a breast cancer histopathological type classification method based on generative adversarial network screening image blocks, which comprises the following steps: acquiring a breast cancer histopathological type image data set, and further comprises the following steps: preprocessing breast cancer histopathological type images; enabling the generative adversarial network to screen normal regions in the benign image blocks and the malignant image blocks; enabling the generative adversarial network to screen benign regions in the malignant image blocks; and classifying thebreast cancer histopathological images by using a convolutional neural network based on cyclic dense connection. According to the invention, the improved unsupervised generative adversarial network isadopted to learn the data distribution of the normal pathology image and the benign tumor pathology image respectively, so that the benign tumor area and the normal area in the malignant tumor pathology image and the normal area in the benign tumor pathology image can be screened; and the possibility is provided for assisting doctors to diagnose the illness state more accurately and more quicklyto the maximum extent.

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.

The invention discloses a TCTP gene space-time specificity conditional and tissue specific gene knock-down animal model construction kit based on a recombinase recognition system, a targeting vector and a construction method thereof of the targeting vector, a mouse TCTP gene specific gene knock-down animal model and a sperm thereof, an oocyte thereof, an oosperm thereof, an embryo thereof, a filial generation thereof, a tissue thereof or a cell thereof as well as applications of the products and methods in an immunology research, researches of immunotoxicology, immunological rejection and andmechanisms thereof, researches of cancer cell apoptosis mechanisms and cancer targets, a research of targeted cancer therapy, safety evaluation, a purpose in the pharmacodynamic evaluation aspect, making of a tumor pathological model and a preparation of a disease treating medicine. By using a homologous recombination technology and an embryonic stem cell technology, a stably genetic TCTP gene knockout mouse is constructed; and therefore, embryonic death caused by knockout of the gene is avoided; and important significance in researches of the TCTP gene in cancer occurrence, progression and treatment are realized.

The invention relates to a kit for the pathologic diagnosis of tumors. The kit comprises a probe for the pathologic diagnosis of the tumors, wherein the probe comprises a gold nanoparticle cluster, an antibody of a tumor specific marker and CBB (Coomassie brilliant blue) in the molar ratio of (1-10):(1-100):(1-100); the gold nanoparticle cluster and the antibody of the tumor specific marker are connected in the manner of click chemistry; and the CBB and the gold nanoparticle cluster connected with the antibody of the tumor specific marker are combined in a static manner. The kit has high accuracy on the pathologic diagnosis of the tumors. In addition, the invention also provides a method for staining tissue sections.

The application discloses a non-human mammal model constructing kit with conditional gene knock-down of TCTP genes, a targeting vector, a constructing method of the targeting vector, a non-human mammal TCTP gene whole-body gene knock-down animal model, serums, an egg cell, a fertilized egg, an embryo, an offspring, tissues or cells of the animal model, application of products and the method in immunology research, research of immunotoxicology, immune rejection response and mechanism thereof, research of a cancer cell apoptosis mechanism, reach of a cancer target and cancer targeted therapy, safety evaluation and pharmacodynamic evaluation, production of a tumor pathologic model and preparation of drugs for preparing diseases based on a recombinase recognition system. The stably-inherited TCTP gene is constructed by using a homologous recombination technology and an embryonic stem cell technology for whole-body knock-down of a mouse, so that embryonic lethality caused by whole-body knock-down of the gene is avoided; the invention has important significance for researching occurrence and development of cancer and cancer treatment of the TCTP gene.

The invention relates to the identification of the SUFU (supressor of fused) gene as a tumor suppressor gene and the identification of mutations of the SUFU gene that are associated with the development of cancer, particularly medulloblastoma. The invention provides methods for determining a diagnosis, prognosis or risk of a tumor pathology in a subject involving a SUFU gene mutation, where the method comprises detecting a SUFU gene mutation in DNA from a subject. The SUFU gene comprises exons 1 through 12 and the mutation is associated with the tumor pathology.

The invention provides a tumor interstitial ratio judgment method and system based on an image processing algorithm. The tumor interstitial ratio judgment method comprises the steps OF: M1, reading tumor pathological section HE immunohistochemical images; M2, selecting an image of which the average gray value and of which the blurring degree are within a preset range; M3, preprocessing the selected image based on an image preprocessing algorithm to obtain a preprocessed image; M4, segmenting the preprocessed image is; and M5, obtaining a segmentation result, marking the segmentation result, and calculating the mass ratio between tumors. According to the method, the accuracy of data is greatly improved, and a set of tumor interstitial ratio calculation mode with higher efficiency and higherprecision is provided.

The invention relates to a tumor pathological nuclear morphological parameter measuring device, and belongs to the technical field of medical devices. The tumor pathological nuclear morphological parameter measuring device provided by the invention comprises a device main body, wherein an observation platform is arranged on the device main body; a microscopic observation mirror is arranged on the upper side of the observation platform; a metal supporting box is arranged on the lower side of the observation platform; a dyeing machine is arranged in the metal supporting box; a metal extending platform is arranged on the right side of the metal supporting box; a metal fixing post is arranged on the upper side of the metal extending platform; a supporting plate is arranged on the upper side of the metal fixing post; a keyboard groove is formed in the supporting plate; a keyboard is arranged in the keyboard groove; a supporting cross plate is arranged on the upper side of the supporting plate; a display base is arranged on the rear side of the supporting cross plate; a display supporting frame is arranged on the upper side of the display base; a display is arranged on the upper side of the display supporting frame. The tumor pathological nuclear morphological parameter measuring device is complete in function and convenient to use, saves time and labor, and is safe and high in efficiency when a benign tumor or a maglinant tumor is distinguished, and the histopathological grading and the prognosis judgment of the tumor are performed; the work difficulty of medical staff is reduced.

The invention discloses a screening model of an anti-breast cancer tumor drug. The screening model is constructed by the following specific steps: 1) modifying the surface of a hollow fiber reactor byusing acetic acid plasma, and sterilizing; 2) separating a breast cancer tumor single cell; 3) implanting the breast cancer tumor single cell in the hollow fiber reactor, and performing cell attachment culture; 4) determining a target drug, using a health mouse as an administration object, taking the hollow fiber reactor and implanting in the back of the mouse, after 24 h, establishing a mouse breast cancer tumor pathological model; 5) applying the target drug to the mouse breast cancer tumor pathological model, administrating once every 1-2 days, and constructing the screening model of the anti-breast cancer tumor drug. The screening model is capable of rapidly performing efficacy evaluation of the anti-breast cancer tumor drug, greatly shortening time needed by a pharmacological experiment of a traditional mouse xenograft transplantation model, wherein the time does not exceed 20 days from the experiment to a result, and reducing clinical experiment cost, and is easy to popularize.

The invention discloses application of ginsenoside Rg3 in combination with GP as an antitumor drug. A mouse Lewis lung cancer cell line (LLC) is selected and inoculated to the right armpit of a C57BL / 6N mouse, and the influence of ginsenoside Rg3 and Rg3 in combination with GP on Lewis lung cancer is observed; hematoxylin-eosin staining is performed on the liver, kidney, spleen and tumors, and pathological changes of ginsenoside Rg3 in combination with GP on the liver, kidney, spleen and tumors of mice with the Lewis lung cancer are detected; and tumor tissues are subjected to immunohistochemical staining, and the density of blood vessels in tumors and the expression of tumor platelet surface activation markers are detected. The conclusion is that the ginsenoside Rg3 in combination with GPcan enhance the effects of ginsenoside Rg3 of inhibiting the tumor growth of the mice with the Lewis lung cancer and inhibiting tumor angiogenesis, and the tumor inhibition effect of the ginsenosideRg3 is possibly and closely related to CD62P expression reduction; and the ginsenoside Rg3 in combination with GP can achieve the synergistic and toxicity-reducing effects.

The invention discloses a tumor blood platelet RNA quantitative detection model for tumor early screening. The model comprises PCR (polymerase chain reaction) detection specific primers. The PCR detection specific primers include an F-end primer and an RT primer which are shown as SEQ ID NO.1, an F-end primer and a RT primer shown as SEQ ID NO.2, an F-end primer and an RT primer which are shown as SEQ ID NO.3, an F-end primer and an RT primer which are shown as SEQ ID NO.4, an F-end primer and an RT primer which are shown as SEQ ID NO.5, an F-end primer and an RT primer which are shown as SEQ ID NO.6, an F-end primer and an RT primer which are shown as SEQ ID NO.7, an F-end primer and an RT primer which are shown as SEQ ID NO.8 and an F-end primer and an RT primer which are shown as SEQ ID NO.9. The invention further discloses a tumor blood platelet RNA quantitative detection method for tumor early screening. The tumor blood platelet RNA quantitative detection model and method has the advantages that tumor early screening is realized, tumor pathological identification and clinical diagnosis are assisted, and survival rate of patients is increased.

Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.

The invention discloses a method for recognizing a lesion area in a thyroid follicular tumor tissue pathological image, and predicts gene mutation. The method is an automatic auxiliary diagnosis technology based on a deep learning method, a lesion area in a thyroid follicular tumor pathological tissue slice image is automatically positioned by using big data and a deep convolutional neural network algorithm, and a pathological histological type and a gene mutation type of the lesion area are automatically recognized. According to the pathological tissue image, recognizing cases simultaneously carrying RAS and other driver gene mutations, and realizing histological classification of the follicular thyroid tumor and prediction of related gene mutations. According to the method, information is provided for clinicians, pathological diagnosis and clinical decision making are assisted, and development of digital pathology and precise medical treatment is promoted.

The invention discloses an adjustable fixator for bone tumor pathological specimen sampling, which comprises a device base, a nesting rod, an embedded rod and a workbench, wherein the nesting rod is fixedly connected to one side of the top of the device base; the embedded rod is movably connected to the interior of the nesting rod; the top of the embedded rod is fixedly connected with the workbench; a positioning bolt is connected to one side of the top of the nesting rod in an embedded manner; the front surface of the workbench is movably connected with an occlusion block; a second positioning bolt is connected to the bottom end of the occlusion block in an embedded manner; and the top of the occlusion block is fixedly connected with a movable block; and the movable block improves the flexibility of the device main body. The fixing mechanism can be used for firmly fixing a bone specimen; when a medical worker cuts the specimen, the specimen does not shake, and the stability of the device main body is improved; due to the design of a workbench cleaning mechanism, the medical staff can conveniently and rapidly clean bone scraps on the surface of the workbench, the convenience of thedevice main body is improved through a rotating block, and the adjustable fixator is suitable for being used for sampling bone tumor pathological specimens and has wide development prospects in the future.

A diagnostic method, in which patient tissue samples are taken, microassay are prepared, specific anti-viral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: if the number of blood cells infected by any two or more viruses exceeds 50±10% in patients without signs of oncological pathology, a diagnostic conclusion is drawn of a high danger of oncological illness in connection with immune system ineffectiveness; if the number of cells infected by any two or more viruses exceeds 50±10% in patients with diagnosed oncological illnesses, a diagnostic conclusion of the cancer tumor's low sensitivity to chemotherapy and the perspective of quick tumor metastasis is drawn.

The invention relates to a structure, a preparation and applications of a reduction responsive fluorescent probe, and belongs to the field of organic fluorescent probes. Based on the problem of generally not high signal-to-noise ratio of the imaging of the existing fluorescent probe, the invention discloses an efficient fluorescent nano-probe, wherein the outermost layer is albumin, the middle layer is a hydrophilic polymer block, and the inner layer is a hydrophobic polymer block core simultaneously coupled with a reduction-responsive chemical bond and a fluorescent dye. According to the invention, in a non-reducing environment, the fluorescent molecules in the nanometer core are subjected to fluorescence quenching, so that the nano-probe is in an extremely low fluorescence state; in a reducing environment, the fluorescence molecules are subjected to core / shell transition under the combined action of a reducing agent and nano-shell albumin, so that the nano-probe is converted to an extremely high fluorescence state so as to achieve high signal-to-noise ratio; and the nano-probe disclosed by the invention can be used for specific living body imaging of tumors, imaging-guided operations, tumor-related lymph node imaging, tumor pathological section imaging and the like.

The invention concerns Au(III) complexes of the type [AuIIIX2(Pdtc)] (X=halogen, pseudo-halogen; pdtc=peptide- / esterified peptidedithiocarbamato) which are able to both maintain the antitumor properties and the lack of nephrotoxic side-effects of the previously reported Au(III)-dithiocarbamato complexes, together with an improved bioavailability through the peptide-mediated cellular internalization. The Au(III) complexes described have shown a significant biological activity on human tumor cell lines and, thus, they can be advantageously used as antineoplastic agents. The preparation method and use for the treatment of tumor pathologies of the Au(III) complexes of the invention are further described.

A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.

The invention relates to a tumor pathological diagnosis method based on a molecular fragment spectrum generated by interaction of light and substances, belongs to the technical field of spectrum detection, and solves the problems that pre-operation imaging diagnosis cannot be highly consistent with intraoperative conditions, pathological biopsy needs to be carried out during an operation, frozen pathological biopsy depends on experience of pathologists, and the diagnosis accuracy is not high. Laser-induced breakdown spectroscopy data of a tumor is acquired by using a laser-induced breakdown spectroscopy measurement system. Molecular fragment bands in the identification data serve as diagnosis and identification features to calculate the intensity ratio of the molecular fragment bands, andthe number of the diagnosis and identification features is expanded. A brain-like computing spiking neural network model is constructed according to the ratio characteristics, and diagnosis and identification are carried out on unknown molecular fragment spectral data by applying the obtained spiking neural network model.

The invention belongs to the technical field of auxiliary medical equipment, and particularly relates to tumor pathological image display equipment capable of realizing projection separation. The equipment comprises a controller, and a microscope, a memory and a plurality of sub-display devices which are connected to the controller, wherein each sub-display device comprises a table top, a vertical plate, an image display assembly, an image shooting assembly and a projection assembly; the table top comprises a fixed top panel, a movable top panel and an arrangement area; an image display assembly and an image shooting assembly are arranged in the arrangement area; a storage cavity with the top communicating with the arrangement area is formed in the vertical plate, a projection assembly is arranged in the storage cavity, and the projection assembly comprises a movable mounting plate, an illuminating lamp and a projection plate. In the equipment, the image display assembly is used for displaying an image and a local magnified image, so that a doctor can watch the image for a long time, the image shooting assembly is used for locally shooting the displayed image, image details are conveniently observed, and the projection assembly is used for carrying out lossless zoning on the image rapid positioning is facilitated, so that the equipment can meet the requirements of different doctors.

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and / or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and / or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

The invention dislcoses a probe for tumor pathological diagnosis and a use method thereof. The probe comprises a positioning support and a probe installation assembly, the positioning support comprises a left supporting frame, a right supporting frame and a top plate, the left supporting frame and the right supporting frame are symmetrically installed on the two sides of the top plate, the left supporting frame and the right supporting frame are each of an L-shaped structure, a through hole is formed in the center of the top plate. A probe sleeve is installed at the through hole, the probe installation assembly comprises a connecting sleeve, a diagnosis probe, a connecting rod and a pressing assembly, the structural design is novel, use is convenient, positioning of a puncture part can be achieved, tumor tissue sampling is improved, the diagnosis efficiency is improved, and in addition, pain of a patient can be relieved in the puncture sampling process.

The invention discloses a serologic biomarker miR-106b (microRNA) for detecting ovarian tumor. A sequence of the serologic biomarker miR-106b (microRNA) is uaaagugcugacagugcagau. The invention further discloses application of the serologic biomarker miR-106b in preparing a kit for screening ovarian tumor or aiding in pathological appraisal and clinical diagnosis of ovarian tumor. The kit comprises a reverse transcription system and a primer system / primer probe system. The reverse transcription system comprises reverse transcriptase, reverse transcription system buffer and RNA (ribonucleic acid) enzyme inhibitor. The primer system comprises a stem-loop reverse transcription primer and a cDNA (complentary DNA) amplification primer in the miR-106b, and a stem-loop reverse transcription primer and an amplification primer in miR-16. The primer probe system comprises a stem-loop reverse transcription primer, a cDNA amplification primer and a probe in the miR-106b, and a stem-loop reverse transcription primer, an amplification primer and a probe in the miR-16.

The invention relates to the technical field of pathological specimen measurement, and discloses a specimen measuring device and measuring method for tumor pathology. The specimen measuring device comprises a camera obscura assembly, the camera obscura assembly comprises a box body, an opening and closing plate, a placing plate, a glass cover piece, photosensitive specialty paper, a specimen placing groove and a first shading plate, the opening and closing plate is hinged to the outer surface of the box body, and the placing plate is arranged in the box body; when the specimen is measured, firstly, the photosensitive specialty paper is fixed in the box body, then the specimen is placed in the specimen placing groove, meanwhile, the lamp source is started to emit light to irradiate the photosensitive specialty paper in the box body, the specimen partially blocks the light, so that the lower photosensitive specialty paper forms a patch consistent with the specimen in shape, the shape of the plaque is consistent with the shape of the specimen, and the size of the specimen can be obtained by indirectly measuring the size of the plaque, so that a user can perform measurement without directly contacting the specimen, and the convenience and the safety of measurement are greatly improved.